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Sleeping Beauty transposition: from biology to applications
Suneel A. Narayanavaria, Shreevathsa S. Chilkundaa, Zoltan Ivicsb and Zsuzsanna Izsvaka
aMobile DNA, Max Delbr€uck Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany; bDivision of Medical
Biotechnology, Paul Ehrlich Institute, Langen, Germany
ABSTRACT
Sleeping Beauty (SB) is the first synthetic DNA transposon that was shown to be active in a wide
variety of species. Here, we review studies from the last two decades addressing both basic biol-
ogy and applications of this transposon. We discuss how host–transposon interaction modulates
transposition at different steps of the transposition reaction. We also discuss how the transposon
was translated for gene delivery and gene discovery purposes. We critically review the system in
clinical, pre-clinical and non-clinical settings as a non-viral gene delivery tool in comparison with
viral technologies. We also discuss emerging SB-based hybrid vectors aimed at combining the
attractive safety features of the transposon with effective viral delivery. The success of the SB-
based technology can be fundamentally attributed to being able to insert fairly randomly into
genomic regions that allow stable long-term expression of the delivered transgene cassette. SB
has emerged as an efficient and economical toolkit for safe and efficient gene delivery for med-
ical applications.
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Transposable elements (TEs) are repetitive sequences
that are components of nearly all genomes (Huang
et al., 2012). Approximately 50% of the human genome
is derived from TEs (Cordaux & Batzer, 2009; Lander
et al., 2001). The vast majority of TEs accumulate inacti-
vating mutations over evolutionary time to give rise to a
fraction of the genome that is often called “junk DNA”.
Recent studies suggest that the portion of the inactive
mass is going through a recycling, “gain of function”
process, yet to be fully deciphered (Lander et al., 2001;
Prak & Kazazian, 2000). In an attempt to turn the “junk”
into a “jewel”, a reverse engineering approach was
applied to eliminate the accumulated mutations of Tc1-
family transposons in fish genomes, which resulted in a
synthetic transposon system known as Sleeping Beauty
(SB) (Ivics et al., 1997). SB not only represents the first
DNA-based TE ever shown to be active in vertebrates,
but the first functional gene ever reconstructed from an
inactive, ancient genetic material, for which an active,
naturally occurring copy either does not exist or has not
yet been isolated. Currently, the hyperactive version of
SB (SB100X) is one of the most active transposon in ver-
tebrates (Mates et al., 2009). SB gave an opportunity to
understand several aspects of transposon regulation. It
is assumed that, unlike viruses, TEs and the host have
coevolved in a way that permits propagation of the
transposon, but minimizes damage to the host. The SB
system is an excellent tool to model horizontal gene
transfer or the establishment of a complex interaction
network between a vertebrate host and a transposon.
The accumulated knowledge of transposon biology
was also applied to establish a transposon-based tech-
nology platform for genome engineering in vertebrate
species, including cancer research, gene annotation, ver-
tebrate transgenesis or gene therapy (Ivics et al., 2004).
The sleeping beauty transposon
SB belongs to the Tc1/mariner superfamily of DNA
transposons (Plasterk et al., 1999) comprising a trans-
posase gene flanked by inverted repeats (IRs) contain-
ing recognition sequences for transposase binding
(Figure 1A).
Transposases of the Tc1/mariner superfamily, the
bacterial insertion sequence (IS) elements, retroviral
integrases and the V(D)J recombinase contain an evolu-
tionarily and functionally conserved catalytic domain,
having a DDE/D (Asp, Asp, Glu) motif. DDE/D
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recombinases catalyze a remarkably similar overall
chemistry of DNA recombination (Craig, 1995; Ivics &
Izsvak, 2015). Each IR unit of these elements is
200–250 bp in length, and possesses two transposase
binding sites known as direct repeats (DRs) that are
15–20 bp in length. The left IR is not identical to the
right IR, as the former contains an extra “half direct
repeat (HDR)” of the transposase-binding site acting as
a transpositional enhancer (Izsvak et al., 2002) and the
untranslated regions (UTR) regions which appear to
regulate transposition transcriptionally (Moldt et al.,
2007; Walisko et al., 2008) (Figure 1A).
Mechanism of sleeping beauty transposition
During non-replicative, “cut and paste” transposition of
SB, the transposase first binds to its recognition
sequences (DRs) of the transposon (Figure 2). During
synaptic complex formation, the two transposon ends
are brought together. The transposon is liberated by
excision, and the excised molecule is mobilized
between the donor and the reintegration loci. The
transposase acts at least as a tetramer (Izsvak et al.,
2002). Excision leaves a footprint (3 bp) at the donor
site while integration results in target site duplications
(Ivics et al., 1997) (Figure 2).
Structure of the sleeping beauty transposase
The SB transposase contains an N-terminal DNA-binding
domain (DBD), a nuclear-localizing signal (NLS) involved
in nuclear transport and a C-terminal catalytic domain
(DDE) involved in the DNA cleavage and strand transfer
reactions (Ivics et al., 1997)(Figure 1B). The bipartite
DBD consists of two subdomains; namely, the PAI and
RED (PAIþ RED¼ PAIRED; connected by a linker), and
shows similarity to the paired domain of the PAX tran-
scription factor family (Czerny et al., 1993). Both the PAI
and RED subdomains are predicted to possess three
alpha helices, two of which form a helix-turn-helix
(HTH), found in many DNA-binding proteins (Aravind
et al., 2005). Similarly to other DDE recombinases, the
catalytic domain is predicted to have an RNaseH-like
fold (Hickman et al., 2010; Rice & Baker, 2001). Despite
multiple attempts over the last decade, the crystal
structure of the full-length SB transposase remains
unknown. Alternatively, successful studies have been
reported on solving the structure of functional domains
separately (Carpentier et al., 2014; Voigt et al., 2016)
(Figure 3). The closest structure to SB is Mos1
(Richardson et al., 2009). Mos1 is a mariner-family trans-
posase that, similarly to SB, belongs to the Tc1/mariner
superfamily.
The DNA-binding domain
The NMR structure of the PAI domain confirms
previous predictions (Izsvak et al., 2002), in that it
possesses three alpha helices (helix1¼ 12–22; helix2-
¼ 29–33; helix3¼ 39–55) (Carpentier et al., 2014)
(Figure 1B, Figure 3A). Although the structure of a
PAI domain/DNA substrate complex is currently
unknown, the residues involved in DNA binding were
identified to be in the second alpha helix, connecting
HTH loop and the third alpha helix (residues 28,
29,31, 33–36, 38–43, 47) (Figure 1B, Figure 3A). The
PAI domain binds to the DR-core sequence located
within the inner and outer DRs. Upon comparison of
SB-PAI domain with other DBDs of the related
Tc1/mariner family members (e.g. Tc3 and Mos1), the
Figure 1. Structure of the Sleeping Beauty transposon system.
(A) The Sleeping Beauty (SB) system. The transposase gene
(yellow rectangle) is flanked by left and right inverted repeats
(IRs) (arrows). Each IR contains two direct repeats (DR), an
inner (DRI; orange) and an outer (DRO; brown) to which the
transposase (yellow pie) binds at the respective core regions
(gray thick line). (B) Domain organization of the transposase:
The transposase consists of an N-terminal, DNA-binding
domain (PAIþ RED), a nuclear localization signal (NLS), an
interdomain linker and a C-terminal, catalytic domain (CD).
The CD has a clamp loop with a glycine strip (GGG) and three
conserved catalytic residues (DDE). Both PAI and RED domains
contain three alpha-helices and are separated from each other
by a GRRR AT-hook motif. Numbers in the lowest panel repre-
sent residues that directly interact with the DNA. A color ver-
sion of the figure is available online (see color version of this
figure at www.informahealthcare.com/bmg).
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main differences are observed in the length and rela-
tive orientations of the alpha helices. As PAX5 has
the highest amino acid sequence similarity to the
SB-PAI than Tc3 or Mos1, we superimposed PAX5
and SB-PAI structures (Figure 3B). The PAI domain of
SB differs from PAX5 with respect to Helix-2 in spite
of high similarity at sequence level, and this could
be attributed to the simple fact that the structure of
SB’s PAI was obtained without DNA whereas the
structure of PAX5 was deciphered in-complex with
DNA (Figure 3B).
The catalytic domain
The structure of the SB transposase catalytic domain
along with the flexible inter-domain linker was recently
crystalized and used to model the SB transposase/trans-
poson complex (Voigt et al., 2016). As expected (Rice &
Baker, 2001), the catalytic domain of the SB transposase
contains a canonical RNaseH-fold, consisting of centrally
located b-sheets (five-stranded) surrounded by a-helices
(five) (Figure 3C). The catalytic residues (D153, D244
and E279) are assembled in close proximity establishing
Figure 2. Host factors assist Sleeping Beauty transposition. Schematic representation of transposon mobilization: following expres-
sion (1) SB (red spheres) binds to the IRs (2) leading to the formation of a synaptic complex (3i) resulting in excision (3ii) from
the donor DNA. The excised element then inserts into a TA dinucleotide () (3iii), which is duplicated following a successful inte-
gration. Excision would leave a 3-bp footprint behind. Role of host factors in regulating transposition: Transcriptional control:
the high mobility group protein, HMGXB4 upregulates SB transcription (green arrow). Upon expression, the SB transposase
antagonizes the effect of HMGXB4. The synaptic complex: SB recruits the high mobility group protein, HMGB1 (green ovals),
which promotes synaptic complex assembly starting at the inner DRs. Prevention of autointegration: The host factor, barrier-to-
autointegration factor (BAF1) prevents suicidal self-integration. Excision site repair: The Ku70/80 complex of the non-homologous
end joining repair pathway (NHEJ) assists healing double stranded DNA damage generated upon transposon excision. Cell cycle
modulation: SB modulates cell cycle transition via Miz1 by down regulating Cyclin D1 expression. A color version of the figure is
available online (see color version of this figure at www.informahealthcare.com/bmg).
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an active site conformation, similarly to the one
observed in the crystal structure of the MOS1 transpo-
sase (Richardson et al., 2009). In addition, the catalytic
domain also contains a flexible “clamp loop” having a
glycine-rich strip (PTVKHGGG; with three consecutive
glycine residues), which is inserted within the RNaseH-
fold (Figure 1B, Figure 3C). The SB-RNaseH superim-
poses closely (rmsd of 1.97 Å) with MOS1, except in the
linker and the clamp loop domains (Figure 3D). The
clamp loop assumes an unusually bent conformation (at
three consecutive glycine residues) that is predicted to
form a protein–protein interface between protein
monomers (Figure 3E). As in MOS1 (Richardson et al.,
2009), this interface might bring two catalytic domains
into close proximity with their active sites facing each
other during synaptic assembly. The clamp loops of
both protomers form reciprocal interactions with the
RNaseH core of the partner molecule (Figure 3E). The
clamp loop also contains two short anti-parallel
b-strands, forming a b-hairpin that interacts with the
main chain of the interdomain linker of the partner mol-
ecule (Figure 3E). Due to the lack of the availability of a
co-crystal containing the substrate DNA with transpo-
sase, the authors generated an in silico transposon cap-
ture complex (TCC) model. The TCC model contains the
full-length transposase complexed with target DNA. In
the proposed model, the positively charged groove of
the catalytic domain can accommodate the bent
Figure 3. Structure of the Sleeping Beauty transposase. (A) Structure of the PAI domain as deciphered by NMR. The structure con-
sists of three a helices (in orange; PDB 2M8E). Amino acids involved in DNA binding are highlighted in gray. (B) Superimposition
of PAX5 (in green; PDB 1K78) with the PAI domain. The differences are highlighted by a dotted circle. (C) Structure of the cata-
lytic domain (CD; in orange; PDB 5CR4) showing the N-terminal interdomain linker in gray, a helices in orange, b sheets in purple.
The glycine strip (shown in cyan) is part of the clamp loop. The three catalytic residues, DDE are shown in gray. (D)
Superimposition of the catalytic domain (CD) of SB (red) on MOS1 structure (cyan; PDB 3HOS). Note that main differences among
them are located in the clamp loop (circled dotted line). (E) The potential role of the clamp loops in SB dimerization. (F) The
mutation (I212S) further improves the hyperactivity of SB100X (Voigt et al., 2016). The DAVQ stretch is used as a reference to
show the position of I-212 (refer the adjoining inlet). The structural analysis was done by the Chimera version of 1.10.2 (Pettersen
et al., 2004). A color version of the figure is available online (see color version of this figure at www.informahealthcare.com/bmg).
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target DNA. The model is in conjunction with earlier
studies showing that SB prefers bendable, even severely
distorted target sites (Vigdal et al., 2002). Using the TCC
model, it was also possible to rationalize previous
hyperactive mutations (SB100X), and also design novel
hyperactive variants (Voigt et al., 2016). The structure-
based engineering might pave the way for the future
development of designer transposases with differential
activities and target site specificities.
Transposon–host interactions
SB is a synthetic transposon, mimicking an ancestral
element that was highly successful in the genomes of
various fish species>10 million years ago (Ivics et al.,
1997). Inactive SB-like elements are widespread in vari-
ous fish species, are also present in certain amphibian
species but never colonized other vertebrates (Ivics
et al., 1996). Thus, no SB-like sequences are present in
mammals, including humans. In fact, the human gen-
ome consists of around 3% inactivated DNA transpo-
sons (Cordaux & Batzer, 2009; Lander et al., 2001). The
most closely related sequences to SB are the human
mariner elements, belonging to the same Tc1/mariner
superfamily of transposons. While no active DNA trans-
poson is present in the human genome, certain copies
have been “recycled” in a domestication process, and
gained a novel cellular function. For example, specific
mariner loci gave rise to microRNA (miRNA) genes
(Borchert et al., 2011; Smalheiser & Torvik, 2005), and
five piggyBac-derived elements (PGBD1–5) are under
selection presumably to perform novel, yet to be char-
acterized cellular activities. Importantly, the SB transpo-
sase is highly specific with respect to the sequences
that it can mobilize, and does not cross-mobilize related
Tdr1 elements in the zebrafish genome (Ivics et al.,
1997; Izsvak & Ivics, 2004). Surprisingly, by contrast,
PGBD5 has been reported to be capable of mobilizing
the insect-derived gene transfer tool, piggyBac (Henssen
et al., 2015; Ivics, 2016).
Despite being resident only in fish, the transpos-
ition reaction catalyzed by SB is supported in all
Chordata species tested (Izsvak et al., 2000), including
the non-vertebrate Ciona intestinalis (Hozumi et al.,
2013). The only report where SB was shown to suc-
cessfully transpose outside chordates was an inverte-
brate, the Black Legged Tick (Ixodes scapularis,
Phylum Arthropoda) (Kurtti et al., 2008). Remarkably,
the insect I. scapularis seems to be able to cross the
Chordata-specific barrier as an animal/human patho-
gen (e.g. Lyme disease).
Compared to SB, piggyBac, originating from an
insect (Trichoplusia ni) (Lobo et al., 2006) has a
relatively loose host requirement, because it can
transpose even in human cells. In contrast, the P
element has an extreme species-specificity, and it is
active only in a single species (Drosophila mela-
nogaster). Previously, it was generally accepted that a
transposon capable of transposing in vitro does not
require host-encoded factors. Furthermore, transpo-
sons with wide host range were assumed to require
no host factors (Raz et al., 1998; Vos et al., 1996).
Both assumptions are proved to be false. First,
although the nematode Tc1 is capable of performing
transposition in vitro, it is not able to support precise
transposition in a phylogenetically distant host
(Schouten et al., 1998; Vos et al., 1996). Second, the
vertebrate-specific SB transposition requires a number
of host factors, but these host-encoded proteins are
evolutionary conserved in vertebrates. The strategy of
recruiting phylogenetically conserved cellular factors
could help to establish a stable host–transposon rela-
tionship upon colonizing a related naïve genome.
A delicate host–transposon relationship is import-
ant for stabilizing long-term transposon–host coexist-
ence. Via its host factors, SB is able to sense and
react to various signaling processes, and participates
in complex interactive regulatory processes involving
evolutionary conserved cellular mechanisms (Figure 3).
Host-encoded factors might enable the transposon to
sense and react to spatio-temporal cellular signals
and help to filter out aberrant transposition products
(Wang et al., 2014c). The transposition reaction might
not work at all or would lose fidelity under condi-
tions, where host factors are not accessible. Indeed,
when a transposon is transferred too far from its ori-
ginal host, the conditions in a new environment
could be suboptimal, and the fidelity of the reaction
could be compromised. For example, the nematode
Tc3 catalyzed aberrant transposition reactions in
zebrafish (Raz et al., 1998). Another example is the
piggyBac that in comparison to SB performs more fre-
quent, aberrant transposition products in mammalian
cells (Wang et al., 2014c). Understanding the delicate
mechanisms of transposon–host coexistence can help
us to design gene transfer tools with minimal geno-
toxicity. The accessibility of a host factor in a given
cell type is likely to affect the efficacy of the reaction.
Indeed, it has been observed that the frequency of
SB transposition varies in different vertebrate cells
(Copeland & Jenkins, 2010; Dupuy et al., 2001; Dupuy
et al., 2002; Fischer et al., 2001; Horie et al., 2001; Luo
et al., 1998; Yant et al., 2000; Yusa et al., 2004). The
host-encoded factors of SB transposition represent a
variety of cellular processes, and are involved at vari-
ous steps of the reaction (Figure 3).
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Transcriptional regulation by HMGXB4
A component of the Wnt signaling pathway (Yamada
et al., 2003), HMGXB4 (also known as HMG2l1), func-
tions as a transcription factor of SB transposase expres-
sion (Walisko et al., 2008). HMGXB4 accesses the 5’-UTR
region of the transposase coding sequence, and pro-
motes its transcription. Besides acting as a transcription
factor, HMGXB4 is able to physically associate with the
transposase protein. Sequestering HMGXB4 not only
abolishes HMGXB4-mediated transcriptional activation,
but has a repressing effect on transcription by the 50-
UTR (Walisko et al., 2008). Thus, SB transposase can
exert a negative feedback regulation on its own expres-
sion with the transposase/HMGXB4 complex acting as a
transcriptional repressor (Figure 3).
DNA methylation enhances sleeping beauty
transposon excision
DNA methylation plays an important role in regulating
the activity of TEs. DNA methylation triggers the forma-
tion of heterochromatin, and is associated with tran-
scriptional repression. Curiously, SB excision is
significantly (100X) enhanced upon CpG methylation
of the SB transposon (Yusa et al., 2004). Similar
enhancement was also observed with other members
of the IR/DR subfamily of transposases, including Frog
Prince, and Minos elements (Jursch et al., 2013), but not
with simple-IR transposons. According to a model, CpG
methylation and subsequent chromatin condensation
promotes synaptic complex formation. The chromatin
condensation helps to bring the distantly located recog-
nition sequences (DRs) of the IR/DR structure into a
close proximity, and results in enhanced transposon
excision (Jursch et al., 2013). This feature might help the
SB transposon to escape CpG methylation-based epi-
genetic repression. Importantly, although SB excision
might be enhanced by a condensed chromatin struc-
ture, transposon integrations are not enriched in het-
erochromatic regions (Gogol-Doring et al., 2016; Huang
et al., 2010).
HMGB1 assists pre-cleavage complex formation
Another high-mobility group protein, HMGB1, a highly
conserved DNA bending protein was identified as a
cofactor of SB transposition (Zayed et al., 2003). It has
been postulated that HMGB1 might induce conform-
ational changes in the transposon DNA, promoting effi-
cient synaptic complex formation. HMGB1 stimulates
preferential binding of the transposase to the inner
DRs, located distantly from the cleavage site, indicating
that HMGB1 might be involved in a regulatory check-
point to enforce synapsis prior catalysis. It is interesting
to note that, HMGB1 has also been shown to be assist-
ing in V(D)J recombination process, by its DNA bending
activity during paired end complex formation (van Gent
et al., 1997) (Figure 3).
Assistance from the host DNA repair to seal
sleeping beauty inflicted DNA damage
In contrast to bacterial DDE/D transposition or V(D)J
recombination, members of the Tc1/mariner superfam-
ily, including SB, do not use a hairpin intermediate to
liberate the transposon (Izsvak et al., 2004; Richardson
et al., 2009). The SB transposase cleaves both strands of
the DNA, thereby leaving a double strand break (DSB)
at the excision site (Izsvak et al., 2004), while transposon
integration is assumed to generate single stranded
gaps. The transposase is not able to seal the gap alone,
and recruits Ku70, along with the DNA-dependent pro-
tein kinase (DNA-PKcs), the key factors of the non-hom-
ologous end joining (NHEJ) pathway of DSB repair to
repair the excision sites (Izsvak et al., 2004; Yant & Kay,
2003) (Figure 3). DNA-PKcs is a limiting factor of SB
transposition, as its cellular level affects the frequency
of the reaction. Potential host-encoded factors involved
at the integration site repair are yet to be identified.
However, the dependence of SB transposition on NHEJ
to seal the gaps is not absolute, NHEJ and HR both con-
tribute to the repair of SB-induced DSBs in mammalian
somatic cells (Figure 3).
Modulation of the cell cycle
Myc-interacting protein zinc finger 1 (Miz1) transcription
factor was identified as an interacting partner of the SB
transposase in a yeast two-hybrid screen (Walisko et al.,
2006). Sequestration of Miz1 results in a down-regula-
tion of Cyclin D1 expression, which eventually leads to
a temporary cell cycle arrest in G1 by interfering with
the G1/S transition (Figure 3). Curiously, a temporary G1
arrest enhances transposition suggesting that SB trans-
position might be favored in the G1 phase of the cell
cycle where the NHEJ pathway of DNA repair is prefer-
entially active (Walisko et al., 2006) (Figure 3). The SB
transposase-induced G1 slowdown by interfering
with cell cycle represents a common strategy shared by
selfish genetic elements (Walisko & Ivics, 2006). Stable
overexpression of SB has also been reported to induce
a G2/M arrest and apoptosis (Galla et al., 2011).
Importantly, the apoptosis is not associated with trans-
posase-induced DNA damage, but most probably a
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response to accumulated transposase proteins in the
nucleus due to overexpression.
Protection from a self-destructive autointegration
process
During the excision process of transposition, the excised
transposon could be re-inserted into its own genome in
a self-disruptive process, known as suicidal autointegra-
tion. This phenomenon has been widely associated with
various retroviruses, but is also observed to affect trans-
position, including SB (Benjamin & Kleckner, 1989;
Garfinkel et al., 2006; Maxwell et al., 1987; Shoemaker
et al., 1981; Wang et al., 2014b). Intriguingly, barrier-to-
autointegration factor (BANF1 also known as BAF1),
a cellular co-factor of certain retroviruses was detected
in higher-order protein complexes containing the SB
transposase. Thus, similarly to certain viruses the SB
transposon/transposase is able to recruit the phylogen-
etically conserved cellular protein BANF1 to avoid sui-
cidal autointegration. BANF1 is presumably acting by
compacting the excised, extracellular transposon gen-
ome to be a less accessible target for autointegration,
thereby promoting productive chromosomal integration
(Wang et al., 2014b) (Figure 3).
Integration site distribution
Sequence analysis of SB integration sites from mamma-
lian cells showed that integration occurs exclusively
into TA dinucleotides (Ivics et al., 1997) (Figure 2).
Target site selection of SB is rather structure- than
sequence-specific, and AT-rich palindromes around the
central TA nucleotide help to form a preferred bendable
DNA structure (Vigdal et al., 2002).
While remobilization of the SB transposon from a
genomic locus exhibits the “local hopping” phenom-
enon, resulting in de novo integrations in the
neighborhood of the donor site within few megabase
window (Keng et al., 2005; Kokubu et al., 2009; Luo
et al., 1998; Yant et al., 2005). In contrast, the integration
profile is fairly random with a small bias toward certain
repetitive elements when initiated from an ectopic mol-
ecule. It was observed that SB targets microsatellite
DNA, MIR-type SINEs (short interspersed elements)
more frequently, while avoids long terminal repeat
(LTR) elements and LINE-1 repeats (Yant et al., 2005).
The close-to-random integration profile of SB has no
overt bias for integrating into genes or near transcrip-
tional regulatory regions of genes (Gogol-Doring et al.,
2016; Yant et al., 2005). Thus, SB integrations display
only a minor enrichment near transcription start sites
(TSSs) or near transcription-associated histone modifica-
tions, including mono-methylated H3K4 (a marker for
enhancer regions) and tri-methylated H3K4 (associated
with promoters of active genes). Integration is not
favored either in regions rich in H3K27me3 (a histone
modification typically associated with transcriptionally
repressed heterochromatin) (Gogol-Doring et al., 2016;
Huang et al., 2010).
This close-to-random integration profile of SB was
confirmed by multiple studies, and was reported from
various organisms and cell types (Ammar et al., 2012a;
Geurts et al., 2006; Gogol-Doring et al., 2016; Huang
et al., 2010; Liu et al., 2005; Moldt et al., 2011; Vigdal
et al., 2002; Voigt et al., 2012; Yant et al., 2005).
Nevertheless, the fairly random integration of SB seems
to be rather exceptional among transposons and inte-
grating viruses in mammalian cells (Figure 4). The Tol2
transposon (also of fish origin) exhibits a preferential
integration into transcription start sites and transcrip-
tional regulatory regions (Ammar et al., 2012a;
Grabundzija et al., 2010; Huang et al., 2010). PiggyBac
has also a biased insertion pattern, and has a pro-
nounced preference for integrating into the 50-transcrip-
tional regulatory regions of genes (Huang et al., 2010;
Figure 4. Integration profile of various integrating vectors. SB (red vertical lines) has a fairly random integration profile when
compared to other DNA transposons like piggyBac (PB) (green vertical lines) and Tol2 (black vertical lines) and viral systems like
HIV (cyan vertical lines) and MLV (green vertical lines). TSS: transcription start site. A color version of the figure is available online
(see color version of this figure at www.informahealthcare.com/bmg).
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Gogol-Doring et al., 2016). Curiously, the piggyBac trans-
poson displays an integration profile highly similar
to that of the MLV retrovirus (de Jong et al., 2014;
Wu et al., 2003), and both MLV integrase and the
piggyBac transposase interact physically with BET pro-
teins for guided integrations to specific chromatin envi-
ronments (de Rijck et al., 2013; Gogol-Doring et al.,
2016; Gupta et al., 2013; Sharma et al., 2013a). The HIV-1
integrase also uses a host tethering complex LEDGF/
p75/PSIP to localize genomic targets (Ciuffi et al., 2005),
and exhibits a strong preference for actively transcribed
genes (Schroder et al., 2002). Whether the close-to-ran-
dom integration profile of SB is guided by a cellular fac-
tor is yet to be explored.
Regulating transcription from sleeping beauty by
RNA interference
Numerous studies indicate that the host-encoded RNA
interference (RNAi) mechanism regulates transposition
by suppressing transposase expression (Robert et al.,
2004; Sijen & Plasterk, 2003; Vastenhouw & Plasterk,
2004; Vastenhouw et al., 2003). In C. elegans, where Tc1
transposition is active, three main mechanisms were
proposed to generate double stranded RNAs (dsRNAs)
that are eventually fed into RNAi pathway of silencing.
Besides bidirectional transcription from the transposon,
dsRNA can also be derived from read-through transcrip-
tion from neighboring genes that can form hairpin
structures of dsRNA (Sijen & Plasterk, 2003).
Alternatively, RNA-directed RNA polymerases can copy
Tc1-transcripts into dsRNA (Sijen & Plasterk, 2003).
Transposase-mediated integration avoids the formation
of multiple, tandem integrations, which could trigger
RNAi-mediated heterochromatin formation and silenc-
ing. Nevertheless, bidirectional (convergent) transcrip-
tion driven by the IRs of SB may lead to the formation
of dsRNA, which can serve as templates for the RNAi
machinery (Moldt et al., 2007; Rauschhuber & Ehrhardt,
2012; Walisko et al., 2008). The distance between the
IRs, e.g. the size of the transposon influences the fre-
quency of the dsRNA production. Interestingly, mariner
elements frequently give rise to short internally deleted
transposon variants, known as miniature inverted
repeat elements (MITEs). Certain mariner-derived MITEs
function as regulatory miRNA genes in the human gen-
ome (Piriyapongsa & Jordan, 2007).
Overproduction inhibition is autoregulatory
The efficiency of transposition reaction is limited by a
phenomenon termed overproduction inhibition (OPI).
OPI is a well-known observation among Tc1/mariner
elements, in which the transposase appears to inhibit
transposition above a certain dosage (Bouuaert et al.,
2014; Grabundzija et al., 2010). Although OPI is involved
in maintaining a stable co-existence between the trans-
poson and its host, it is assumed to be an autoregula-
tory mechanism. The current explanation behind this
phenomenon lies in the observation that excess trans-
posase molecules can saturate the binding sites on the
IRs before productive synapsis could take place, thereby
poisoning the reaction (Claeys Bouuaert et al., 2013).
Alternatively, it is also plausible to assume that improp-
erly folded and/or truncated transposase molecules
inhibit transposition by competing with the active
transposase molecules (reviewed in (Izsvak & Ivics,
2004)).
Translating sleeping beauty transposition
biology
Although SB-like transposons have been inactivated
millions of years ago, the synthetic SB transposon has
started a new “career” in synthetic biology. Importantly,
the accumulated knowledge of the mechanism of its
transposition and its interaction with a vertebrate host
enables us to modulate the transposition reaction for
various applications (Figure 5).
Compared to viral vectors that have been engineered
over decades for their use in gene therapy, the SB sys-
tem was established relatively recently. Since its discov-
ery, it has been used in translational biology, and
proved to be tremendously successful for delivery of
gene cassettes for addressing a variety of questions,
under various molecular contexts and for various appli-
cations both in conjunction with other genetic manipu-
lation tools and as a standalone entity (Figure 5). Its
success in all tested scenarios can be fundamentally
attributed to its exquisite features; first, having an abil-
ity to insert fairly randomly, second, being able to insert
into regions that allow long-term expression of the
delivered cassette and third, allowing low cost vector
production.
The two-component transposon vector system
The basis of using SB as a tool was establishing a two-
component transposon system. As the SB transposase
recognizes the IRs in trans, it was possible to physically
separate the transposase coding sequence from the rec-
ognition motifs for the transposase (DRs). This gene
transfer system is suitable to mobilize a gene of interest
(transgene) flanked by the IRs. The two-component sys-
tem can be placed on various carriers, such as plasmid
DNA (non-viral vector) or can be combined with various
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viruses (hybrid transposon/virus vectors). The transpo-
sase can be also supplied in the form of an mRNA.
It is widely believed that naturally occurring transpo-
sons have not been selected for the highest possible
activity, and are strongly down regulated. Since trans-
posons co-exist with their hosts, transposition activity is
regulated in order to avoid insertional inactivation of
essential genes. Low intrinsic activity, self-regulation
and interaction with cellular host factors appear to
allow wild type transposons to persist in the host with-
out producing serious levels of genetic damage. To
derive an optimal molecular tool, it was necessary to
optimize both components of the SB system.
Optimization efforts generated several hyperactive
variants of the SB transposase (Baus et al., 2005;
Geurts et al., 2003; Mates et al., 2009; Voigt et al., 2016;
Yant et al., 2004; Zayed et al., 2004) (Figure 6).
Molecular evolution was used to generate the hyper-
active SB100X (Mates et al., 2009) (Figure 6). SB100X is
now a component of the first plasmid-based vector sys-
tem that is able to overcome the efficacy problem of
non-viral vectors, and can transfer genes at an efficiency
comparable to integrating viral systems even in stem
and progenitors cells (Mates et al., 2009). SB100X carries
a combination of nine amino acid substitutions, scat-
tered along the coding sequence of the transposase
(Figure 6). Curiously, the individually hyperactive single
amino acid changes cannot be freely combined, and
only a fraction of hyperactive mutations are compatible
with each other (“friendly” mutations). In principle,
Figure 5. Sleeping Beauty transposon-based applications. SB was successfully used for germline transgenesis, in various models
(fish1, frog2, rat3, mouse4, rabbit5, pig6, cow7 and sea squirt8). The SB system has been employed for somatic gene delivery in
various vertebrates, but also in a tick (insect) cell line, ISE6. SB-based gene delivery has been used in several preclinical animal
models. Alternatively, the mutagenic version of the SB can be employed in functional genomics. Insertional mutagenesis screens
can be used to annotate genes in somatic cells (oncogenomics) or in the germline. Abbreviations: eNOS: endothelial nitric oxide
synthase; hUGT1A1: human uridinediphosphoglucuronate glucuronosyltransferase-1A1; statin-AE: angiostatin–endostatin fusion
cassette; DMD: Duchenne muscular dystrophy; DYSF: dysferlin; IDUA: a-L-iduronidase; FAH: fumarylacetoacetate hydrolase; INS:
insulin; L/VDLRs: low-density lipoprotein and very-low-density lipoprotein receptors; miR–29: micro RNA 29; IOD: indoleamine-2,3
dioxygenase; DsRed2: red fluorescent protein 2; GFPs: green fluorescent proteins; siMSTN: siRNA against myostatin; siHTT: siRNA
against Huntington; LAMB3: laminin subunit beta-3; HSVTK: herpes simplex virus thymidine kinase type 1 gene; BCP-ALL: B cell
precursor acute lymphoblastic leukemia). A color version of the figure is available online (see color version of this figure at www.
informahealthcare.com/bmg).
26 S. A. NARAYANAVARI ET AL.
hyperactivity might interfere with the fidelity of the
transposition reaction, and generate more frequent
aberrant transposition products, as it was recently
shown for certain mariner elements (Bouuaert et al.,
2014; Liu & Chalmers, 2014). Importantly, despite its
hyperactive nature, SB100X catalyzes a faithfully precise
transposition reaction. In most of its features, SB100X
does not significantly differ from first-generation SB
transposase, including its stability, OPI profile and affin-
ity to the transposon IRs. In contrast, SB100X is less sen-
sitive to heat shock-induced aggregation, suggesting
that the hyperactive mutagenesis affected the folding
of the transposase in a positive way (Mates et al., 2009).
Perhaps the hyperactivity of SB100X could be further
improved. Indeed, the recently solved crystal structure
of the catalytic domain of the transposase could be a
useful resource of structure-based engineering of tail-
ored SB transposases (Voigt et al., 2016).
The transposon DNA sequences have also undergone
stepwise optimization. First, a minimal vector was con-
structed, where the regulatory sequences, including
promoter/enhancer was removed from the transposon
(Cui et al., 2002). This step created a transcriptionally
neutral vector. Second, transposon excision was
improved by correcting/optimizing the recognition
sequences (IR/DR) of the minimal vector (Cui et al.,
2002; Izsvak et al., 2002). Third, the neighboring
sequence of the IRs was changed to mimic a natural tar-
get site of SB (Cui et al., 2002). This minimal SB system
is highly flexible and can be combined with many add-
itional features. The basic rule is that the IRs should
flank the cargo. The cargo can be a single or multiple
expression cassettes (Kowarz et al., 2015). An advanta-
geous feature of SB, compared to retroviral vectors, is
that it does not require reverse transcription, thus it is
able to express transgenes of highly complex structure
(e.g. repeated motifs, multiple genes, various regulatory
sequences, etc.).
SB-mediated integration supports highly efficient
transgene integration in various cell types (Izsvak et al.,
2000). The list includes somatic or germ cells, differenti-
ated or stem cells essentially in all vertebrate species
(Figure 5). SB is suitable for genetic modification of
both overexpressing and knocking down (Hu et al.,
2011) transgene expression, and can be combined with
other recombination techniques (Grabundzija et al.,
2013) or delivery approaches (non-viral/viral). Indeed, in
the last decade a whole technology platform, a
Figure 6. Multiple sequence alignment of Sleeping Beauty transposase sequences. Hyperactive amino acid mutations (in white
and/or gray) compared to SB10 the original version of the SB transposase, SB10. Hyperactive SB11 and SB100X are targeted for
clinical applications. Multiple sequence alignment was performed using EBI Clustal omega (Sievers et al., 2011) and shading was
performed using BOXSHADE server version 3.21 (http://www.ch.embnet.org/software/BOX_form.html).
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“transposon toolbox”, has been established around SB
(for review see (Ammar et al., 2012b)). SB can be opti-
mized for stable transgene expression (gene/cell ther-
apy, germ line transgenesis). Alternatively, the vector
can be developed as a highly potent mutagenic agent
for gene annotation (somatic/germ line mutagenesis)
(Figure 5).
Sleeping beauty for biotechnology
The SB system has been extensively applied in routine
cell culture (for creating transgenic cell lines and for
gene knockdowns). This plasmid-based system can be
combined with any conventional non-viral delivery
technique (e.g. electroporation, essentially all commer-
cially available transfection reagents, etc.).
Sustainable long-term expression of transgenes
remains a significant challenge for large-scale biotech-
nological applications, especially when antibiotic selec-
tion is not applicable. For such a purpose, SB represents
an attractive transgene expression vector because of its
ability to promote efficient genomic integration in a
variety of mammalian cell types. Transposons, including
SB, piggyBac and Tol2 are suitable for generating poly-
clonal cell pools or clonal cell lines for large scale
(industrial) production of recombinant proteins in
Chinese hamster ovary (CHO) cells (Balasubramanian
et al., 2016).
The characterized expression cassette can be
exchanged relatively simply when the SB cassette is
combined with other molecular engineering tools
(Grabundzija et al., 2013; Petrakis et al., 2012). A power-
ful strategy could be used to express a series of expres-
sion cassettes from the same genomic locus by cassette
exchange using Cre or FLP recombinases (Garrels et al.,
2016a; Grabundzija et al., 2013).
Recently, a protein-based sensor system was also
developed and delivered using SB system for pharma-
cokinetic and pharmacodynamics characterization of
various synthetic analogs of vitamin D3 (Staunstrup
et al., 2011).
Sleeping beauty to generate induced pluripotent
stem cells
Reprogramming of somatic cells provides an oppor-
tunity to generate patient/disease-specific pluripotent
stem cells that can be genetically modified, expanded
and differentiated into multiple cell types for gene
therapy applications. Although retroviral and lentiviral
vector systems have been used for generation of
induced pluripotent stem cells (iPSCs), they are associ-
ated with increased prevalence of tumor formation
(Okita et al., 2007). Attempts have been made to gen-
erate iPS cells using non-viral approaches such as
transposon-based systems (Grabundzija et al., 2013;
Kaji et al., 2009; Muenthaisong et al., 2012; Woltjen
et al., 2009; Yusa et al., 2009). The SB system is sim-
ple, economical and convenient. The reprogramming
efficiency is similarly effective compared to viral vec-
tors (Grabundzija et al., 2013). Indeed, the SB system
has been successfully used for the production of
iPSCs in various organisms and models (Davis et al.,
2013; Fatima et al., 2016; Grabundzija et al., 2013;
Kues et al., 2013; Muenthaisong et al., 2012; Talluri
et al., 2015).
After generating iPSCs, the expression of reprog-
ramming factors needs to be modulated or shut
down for further differentiation or genetic modifica-
tions. For personalized gene or cell therapy, the
patient-derived iPSCs need to be genetically modified
with the therapeutic gene of interest followed by dif-
ferentiation into a specific lineage and transplantation
of these corrected cells back to the patients. To
achieve these goals, SB transposon was engineered to
carry both reprogramming cassette and recognition
motifs for the Cre recombinase (Grabundzija et al.,
2013). After successful reprogramming, the reprogram-
ming cassette could be either excised or exchanged
with a therapeutic gene construct. This strategy
would allow reprogramming and phenotype correc-
tion in a single step. Overall, the SB system repre-
sents a non-viral methodology for the generation of
therapeutically safe pluripotent stem cells.
Enriching for human naïve-like pluripotent stem
cell populations
The ability to derive and stably maintain ground-state
human pluripotent stem cells (hPSCs) that resemble the
cells found in vivo in the inner cell mass has the poten-
tial to be an invaluable tool for researchers developing
stem cell-based therapies. Considerable efforts have
been made to isolate and enrich cells with ground-state
pluripotency in vitro. To date, derivation of human
naïve-like pluripotent stem cell lines has been limited to
a small number of lineages, and their long-term cultur-
ing remains problematic (for review see (Izsvak et al.,
2016)). The SB system has been successfully used for
genetic and phenotypic tagging, selecting and main-
taining naïve-like hPSCs (Wang et al., 2014a; Wang
et al., 2016). hPSCs were tagged by GFP driven by the
LTR7 of HERVH endogenous retrovirus promoter. By
using the reporter, homogeneous hPSC cultures can be
derived, characterized and maintained long term by
repeated re-sorting and re-plating steps. In this setup,
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SB is used to screen for transcriptionally permissive gen-
omic loci in pluripotent stem cells. In addition, SB sup-
ports stable expression of the LTR7-GFP reporter, and
enables to optimize long-term culturing. This strategy
has been reproduced with multiple hPSC lines, includ-
ing embryonic and induced pluripotent stem cells
(Wang et al., 2016).
Optimizing sleeping beauty for gene therapy
The advantages of using the SB system lays in its simpli-
city, unbiased integration pattern, low post-integration
silencing of the transgene and its high cargo capacity.
For therapeutic applications, the SB system has been
further improved addressing efficacy and safety issues
(for reviews (Boehme et al., 2015; Di Matteo et al., 2012;
Hackett et al., 2013; Hou et al., 2015; Ivics & Izsvak, 2006;
Ivics & Izsvak, 2010; Izsvak et al., 2010; Singh et al.,
2015).
An optimal vector for the cargo
Beside sequence and conformation, SB transposition
was shown to be sensitive to the size of the DNA cargo
between the IRs (Izsvak et al., 2000). Bringing the two
IRs in a physical proximity (300 bp) enhances trans-
poson excision (Izsvak et al., 2000). Thus, combining SB
with miniplasmid technologies, such as the minicircle or
the free of antibiotic resistance marker donor molecules
(pFAR) (Marie et al., 2010), improves the rate of SB trans-
position (Sharma et al., 2013b), and address safety
issues in therapeutic applications as these miniplasmids
lack bacterial and antibiotic sequences.
A general feature of DNA transposons is their sensi-
tivity to the size of the cargo. Similarly to other ele-
ments (e.g. piggyBac), the efficacy of transposition
declines over 6 kb of cargo size (Wang et al., 2014c).
However, in contrast to viruses, these transposons do
not have an absolute limit regarding their cargo cap-
acity. Indeed, both SB and piggyBac were reported to
be capable of mobilizing giant molecules of DNA, such
as bacterial artificial chromosomes (BACs) (Li et al.,
2011; Rostovskaya et al., 2012). The strategy of mimick-
ing naturally occurring configurations of certain bacter-
ial transposons that are adapted to carry extra
sequences (e.g. antibiotic resistance genes) could sig-
nificantly increase the cargo capacity of SB (Zayed et al.,
2004). In the “sandwich” (SA) configuration, the cargo
DNA to be mobilized is flanked by two complete SB ele-
ments arranged in an inverted orientation (Zayed et al.,
2004). The SA transposon was demonstrated to have
the ability to transpose up to 18 kb transgenes
(Turchiano et al., 2014).
Targeting transposon integration to specific
genomic loci – on the way to create a safe vector
for gene therapeutic applications
Compared to other integration vectors, SB has a superb
chance to integrate into “genomic safe harbor” loci
(Gogol-Doring et al., 2016), representing currently a saf-
est integrating gene transfer vehicle for application in
human gene therapy. Still, the genotoxic risk is not
zero, and it would be desirable to direct integration to a
“safe harbor” region. For targeted transposon insertion,
at least one component of the transposon system,
either the transposon vector DNA or the transposase
needs to be tethered to defined sites in the human gen-
ome. Proof of principle studies exist demonstrating that
it is possible to direct transposon integration into pre-
determined genomic loci by coupling a site-specific
DNA binding domain (DBD) to the SB transposase
(Ammar et al., 2012a; Ivics et al., 2007; Voigt et al., 2012;
Yant et al., 2007) (Figure 7).
Although SB transposase is sensitive for tagging, it
was possible to fuse various DBDs to the N-terminus of
the transposase (Figure 7A). The first demonstration
that the targeting strategy works was using the TetR/
TRE system. This highly specific DNA-recognition system
consists of the bacterial tetracycline repressor (TetR)
that binds to the tetracycline response element (TRE).
Intriguingly, SB transposon integration could be
enriched by 107-fold to an artificially generated TRE
genomic locus by using a TetR-SB fusion protein in
human HeLa cells (Ivics et al., 2007). The targeting was
region-specific as it occurred in a 2.5 kb window around
the targeted sequence (Ivics et al., 2007).
Fusion of the SB transposase with the GAL4 DBD also
showed an enrichment of transposon insertions in
400-bp window around the targeted sites in cultured
human cells (Yant et al., 2007). Transposon targeting
was also successful using a polydactyl Zn-finger DBD,
E2C, specifically recognizing a unique sequence on
human chromosome 17 (Voigt et al., 2012; Yant et al.,
2007) (Figure 7A).
Another attempt was taking advantage of the locus-
specific integration system of adeno-associated virus
(AAV). The AAV Rep protein binds to naturally existing
recognition sequences (RRSs) in the human genome,
and mediates viral integration into nearby sites. A
fusion protein consisting of the N-terminal DBD of Rep
and the SB transposase was generated. Remarkably, the
Rep-SB yielded a 15-fold enrichment of transposition
near the targeted RRS when supplied in the form of
plasmid DNA (Ammar et al., 2012a) (Figure 7A).
Although it is a real challenge to target a single gen-
omic locus, it might be a feasible approach to target a
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repetitive region in the human genome. Zn-finger DBD
was designed and fused to the SB transposase in a
strategy to target multiple genomic loci simultaneously,
recognizing LINE-1 sequences that occur repetitively in
the human genome (Voigt et al., 2012). Approximately,
a four-fold enrichment of targeted SB insertions was
achieved by targeting LINE-1 repeats, yielding 45%
overall frequency of insertion into LINE-1 genome wide
(Figure 7A).
Targeted transposition events into a chromosomally
integrated TRE or into endogenous matrix attachment
regions (MARs) were recovered by employing targeting
fusion proteins (LexA-Saf) that bind to the engineered
transposon DNA (Ivics et al., 2007) (Figure 7B).
Intriguingly, targeted transposition could also be
achieved without fusing DBD directly to the full-length
SB transposase. Indeed, targeted transposition could be
achieved at similar (or even better) frequencies by fus-
ing the DBD (TetR, Rep) to the N-terminal HTH domain
of the SB transposase, spanning 57 amino acids (N57)
(Ammar et al., 2012a; Ivics et al., 2007; Voigt et al., 2012)
(Figure 7C). N57 was previously shown to mediate pro-
tein–protein interactions between transposase subunits,
and is assumed to bind the HDR (the enhancer
sequence in the IR) (Izsvak et al., 2002). Presumably,
binding of N57 to HDR occurs in the pre-integration
protein-DNA complex. The most significant advantage
of such a molecular design is that the transposase itself
does not need to be engineered. Thus, the negative
effects of direct DBD-transposase fusion on transpos-
ition activity can be eliminated (Figure 7C).
The above studies indicate the feasibility of
directed transposon integration and highlight poten-
tial means for future development. In all these
approaches, the high specificity of the DNA-recogni-
tion domain is crucial. Furthermore, ideally, the
sequence of the selected target site should resemble
an SB target site. In comparison to site-specific gen-
ome editing performed by a ZF-nuclease, the mech-
anism of transposon targeting is principally different.
In contrast to the nuclease-coupled genome-targeting
approaches, the transposition would integrate the
transposon/cargo cassette into the genome without
generating unwanted DSBs in the genome as a side
effect of the reaction (off-target effect). On the other
side, targeting efficacy might not reach 100%, still
transposon targeting could significantly enrich inte-
gration in close proximity of the target site.
Furthermore, in contrast to genome-editing techni-
ques, transposons are suitable to deliver large cargos
in a large variety of cells. In addition, compared to
targeted nuclease approaches, transposition does not
depend on the relatively inefficient homology-
dependent DSB repair of the cell.
To ensure stability of the integration, the remobiliza-
tion (re-hopping) frequency of the integrated cassette
should be negligible. The frequency of SB
Figure 7. Modulating Sleeping Beauty target site specificity.
Strategies to increase target site specificity of Sleeping Beauty
integration. (A) Fusing a DNA-binding domain (DBD) (dark
blue) to the N-terminus of the SB transposase (red). The affin-
ity of DBD to DNA-binding domain region (DBDR) could direct
transposon integration. (B) Co-delivery of a fusion construct
with two DBDs, where DBD1 (cyan) binds an engineered
region in the transposon (DBD1R, cyan), while DBD2 (orange)
recognizes a genomic target sequence (DBD2R, orange). (C)
Alternatively the SB system can be co-delivered with a a
fusion protein, where a DBD (brown) is fused to an N-terminal,
SB transposase derived peptide, N57 (green), a natural inter-
action partner of the full-length SB transposase. A color ver-
sion of the figure is available online (see color version of this
figure at www.informahealthcare.com/bmg).
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remobilization was estimated to be relatively low
(Riordan et al., 2014). Nevertheless, manipulating the
half-life of the transposase by targeting it to cellular
protein degradation pathways could further improve
the safety of SB-mediated gene delivery in clinical
applications.
Sleeping beauty-based transposon-viral hybrids
combine viral delivery with unbiased-random
integration profile
As SB is a non-viral system, the efficacy of its nuclear
delivery is a challenge. Importantly, combining the
transposon vector with cutting-edge non-viral delivery,
like nucleofection and lipofection (for review see (Izsvak
et al., 2010)) has been optimized. Delivery using nucleo-
fection has been approved for clinical application (Maiti
et al., 2013). Nanotechnology seems to open novel
opportunities in efficient non-viral delivery, and can be
combined with cell type specific targeting (Kren et al.,
2009; Wang et al., 2015). In an alternative approach, sev-
eral laboratories have generated transposon-viral hybrid
vectors (Table 1). Viral vectors are excellent gene deliv-
ery vehicles due to their intrinsic ability in transporting
genetic cargos from outside to inside of the cell by
crossing membrane barriers. The transposon-viral
hybrids were constructed with the expectation that the
effectiveness of viral delivery can be combined with the
safety features of SB integration (Figure 8) (Table 1).
Recently, advanced deep sequencing technology
coupled with bioinformatic analysis was utilized to char-
acterize the integration profiles of various vectors (Berry
et al., 2006; de Jong et al., 2014; Gogol-Doring et al.,
2016) (Figure 4) (Table 2). Such studies can help to fore-
cast the potential risk of using different vectors.
Integrating vectors based on both Moloney murine leu-
kemia virus (MLV) have been reported to cause severe
adverse effects after gene transfer in clinical trials.
Besides biased integrations, these vectors could cause
problems by transactivating cellular promoters (e.g.
oncogenes), resulting in clonal expansion of engineered
cells. For instance, the mutagenic potential of MLV-
based vectors have been reported in multiple clinical
gene therapy trials: SCID-X1 (Hacein-Bey-Abina et al.,
2003), (Deichmann et al., 2007; Hacein-Bey-Abina et al.,
2008; Howe et al., 2008; Thrasher et al., 2006), X-CGD
(Stein et al., 2010) and WAS (Braun et al., 2014).
Furthermore, recent analyses also demonstrate that HIV
Table 1. Various sleeping beauty-viral hybrid technologies.
Hybrid technology Delivering vehicle Integration machinery Advantages References
Adeno/SB Recombinant
adenovirus
SB transposase  High transduction efficiency
 SB-mediated unbiased,
random integration profile
 Stable long term expression
 Capable of integrating large
genetic cargos
(Yant et al., 2002)
AAV/SB Recombinant AAV (Zhang et al., 2013)
HSV-1 amplicon/SB HSV-1 (Bowers et al., 2006; de Silva
et al., 2010a; de Silva et al.,
2010b; Peterson et al., 2007)
Baculo/SB Baculovirus (Luo et al., 2012; Turunen
et al., 2014)
IDLV/SB IDLV (Moldt et al., 2011; Staunstrup
et al., 2009; Vink et al., 2009; )
Adeno: adenovirus; AAV: adeno associated virus; IDLV: integrase defective lentivirus; HSV-1: herpes simplex virus 1 amplicon; baculo: baculovirus
Note: The transposase (highlighted in green) and the transposon (highlighted in red) plasmids can be packaged into various recombinant viruses. A col-
ored version is available online (www.informahealthcare.com/bmg).
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integration sites can play a critical role in clonal expan-
sion and persistence of HIV-infected cells (Maldarelli
et al., 2014; Wagner et al., 2014), pinpointing to the risk
of clinical application of HIV-based (lentiviral) vectors.
Importantly, based on the frequencies of integration
into genome safe harbors (GSHs), SB ranks top among
four integrating genetic elements (SB, MLV, HIV,
piggyBac) in the context of human applications (Gogol-
Doring et al., 2016).
In an attempt to modulate the integration profile of
a lentiviral gene delivery system, the viral integration
machinery was replaced with the SB transposase
(Staunstrup et al., 2009; Vink et al., 2009). The employ-
ment of the integrase-defective lentiviral vectors (IDLVs)
Figure 8. Sleeping Beauty transposon-based hybrid vectors. To circumvent the hindrance associated with transfection efficiency of
naked DNA plasmids, the SB system, including both the transposase (Tnpase/SB – green dots for protein) and the transposon
(Tnp/GOI – red) can be packaged into various recombinant viruses like Adeno, AAV, IDLV, HSV-1 and Baculovirus for delivery (by
transduction) into the cytoplasm. The delivery is followed by quick and stable genomic integration of the cargo/GOI, mediated by
the SB system as shown in follow-up qualitative time plot. Abbreviations: GOI: gene of interest; adeno: adenovirus; AAV: adeno
associated virus; IDLV: integrase defective lentivirus; HSV-1: herpes simplex virus 1 amplicon; baculo: baculovirus. A color version
of the figure is available online (see color version of this figure at www.informahealthcare.com/bmg).
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in combination with the SB system made it possible to
alter the biased viral integration profile (Figure 8). The
hybrid vector-mediated transposition reduced the num-
ber of insertions within genes to 30%, overriding the
biased integration profile of the viral vector, and thus
promoting a safer integration profile of SB100X (Moldt
et al., 2011). These data clearly indicate that the
unbiased integration profile of SB can be maintained
independently of the virus used for delivery.
The adeno/transposon system consists of the two-
component transposon system (transposon and SB100X
transposase) delivered by adenoviral vectors (Figure 8).
While adenoviral delivery is efficient, transgene expres-
sion is transient, due to the episomal nature of the
adenovirus (Table 2). The hybrid adeno/transposon vec-
tor enables the integration of the gene of interest,
thereby providing a sustainable expression of the thera-
peutic gene (Yant et al., 2002) (Table 1). This hybrid sys-
tem has been proved to stably express Factor IX as a
treatment for hemophilia B in dogs with negligible tox-
icity (Hausl et al., 2010). The adeno/transposon hybrid
vector has several attractive features. First, it is capable
of integrating large cargos (over 10/20 kbs). Second,
due to the required low amount of therapeutic vector,
the toxicity (provoked immune response) of the admin-
istration is low, and there in no requirement for
repeated administration. Furthermore, by developing
viruses of different tropism, the adenovirus has a prem-
ise to be suitable of targeting different cell types.
AAV vectors have been shown to be one of the most
promising vectors for therapeutic gene delivery, and
were involved in several clinical trials, primarily in slowly
dividing cells (Mingozzi & High, 2011). Due to the stable
integration, the hybrid AAV/transposon (SB100X) pro-
vides sustained gene expression (Zhang et al., 2013),
that generally declines in fast dividing cells, as the sim-
ple AAV vector remains episomal (Table 2). While AAV
vectors have limited cargo capacity, several serotypes
are available. Importantly, the hybrid adeno/transposon
and AAV/transposon vectors exhibit SB100X-directed,
random integration profile.
SB-based hybrid vectors were also developed using
herpes simplex virus (HSV) vectors (Bowers et al., 2006;
de Silva et al., 2010a; de Silva et al., 2010b; Peterson
et al., 2007) (Figure 8). Again, the hybrid system exhibits
unbiased integration profile and a premise to efficiently
deliver and support stable expression in neuronal cells.
The HSV/SB vector has opened up the possibility of
treating early-onset neurological disorders with its cap-
acity to integrate a therapeutic gene within a neuronal
precursor cell population within the fetal brain.
Baculovirus mediates short-term expression in the
transduced cells as a result of the non-replicative and
non-integrative nature of the baculovirus (Chen et al.,
2015; Kost et al., 2005) (Table 2). To circumvent these
problems, a hybrid baculovirus/SB vector was generated
for efficient mammalian cell transduction and sustained
transgene expression (Luo et al., 2012; Turunen et al.,
2014) (Figure 8 and Table 1). The baculovirus-SB vector
combines the efficient baculovirus transduction with
SB-mediated gene expression, alleviating the shortcom-
ing of conventional baculovirus vectors. The integration
preferences for the baculovirus/SB hybrid vector sys-
tems are yet to be determined.
Awakening sleeping beauty in the clinic
SB has proven successful as a gene delivery agent and
the technology reached clinical level just about a dec-
ade following its initial conception (Williams, 2008). The
SB system has met success as a therapeutic vector to
support sustainable, long-term expression in individual
organs (e.g. liver (Wang et al., 2009), lung (Belur et al.,
2003; Liu et al., 2006a), muscle (Escobar et al., 2016;
Muses et al., 2011)) and cells (e.g. retinoid cells (Johnen
et al., 2012), keratinocytes (Ortiz-Urda et al., 2003), pri-
mary T cells etc. (reviewed in (Singh et al., 2015)) of
choice. The clinically relevant cell types tested include
dividing- and non-dividing cells, stem cells (Marg et al.,
2014; Mates et al., 2009; Xue et al., 2009), including
iPSCs (Belay et al., 2010), somatic stem cells and differ-
entiated ones as well.
SB has been systematically tested in several pre-
clinical models (for review see (Izsvak et al., 2010)).
Importantly, no biologically or clinically relevant
immunogenicity has ever been reported that signifi-
cantly affects its applicability. The preclinical models
included a wide range of metabolic disorders, degen-
erative diseases and cancer.
Several metabolic disorders have been successfully
modeled in rodents using the SB system. For example,
it was possible to ameliorate the clinical symptoms
manifested in lysosomal storage disease (Aronovich
et al., 2007; Aronovich et al., 2009), Crigler–Najjar syn-
drome (Wang et al., 2009), type–I Tyrosinemia (Montini
et al., 2002; Pan et al., 2012; Wilber et al., 2007), type–I
diabetes (He et al., 2004) and hypercholesterolemia
(Turunen et al., 2016). It was possible to achieve long-
term expression of human uridinediphosphoglucuro-
nate glucuronosyltransferase-1A1 (pSB-hUGT1A1) in
Gunn rats leading to a significant reduction in serum
bilirubin levels (Wang et al., 2009). Similarly, phenotypic
correction was achieved by expressing fumarylacetoace-
tate hydrolase (FAH) (Montini et al., 2002), human insu-
lin gene precursor (He et al., 2004) and LDLR and VDLR
genes (Turunen et al., 2016) in mouse models. By using
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the SB system, it was also possible to achieve significant
reduction of pulmonary arterial pressure by delivering
endothelial nitric oxide synthase (eNOS) into a rat
model of pulmonary hypertension (Liu et al., 2006a). It
was possible to witness phenotypic correction by long-
term stable expression of Factor-VIII (Kren et al., 2009;
Liu et al., 2006b; Ohlfest et al., 2005b).
Regarding muscular dystrophies, SB-mediated deliv-
ery of dystrophin gene into muscle cells lines followed
by transplantation into mouse muscles resulted in nor-
mal myogenic properties without transforming into
tumors (Muses et al., 2011). Restoration of dysferlin
expression and with signs of muscle regeneration was
also observed (Escobar et al., 2016).
The low immunogenicity of the SB system provides
an opportunity to develop strategies to treat degenera-
tive diseases associated with aging. The SB system was
successfully used to deliver shRNAs against selected
mutant exons of Huntington gene (htt), resulting in up
to 90% repression of the mutant gene (Chen et al.,
2005) in a Huntington disease model. Therapeutic SB
vectors expressing microRNA-29 (miR-29) were also cap-
able of preventing inflammatory macrophage infiltra-
tion in a mouse model of pulmonary fibrosis (Xiao et al.,
2012).
Various therapeutic strategies to monitor (Ohlfest
et al., 2004; Ohlfest et al., 2009) and counter tumor
growth using SB have also been explored. Anti-angio-
genic therapy yielded promising results as it was pos-
sible to achieve tumor regression by delivering
endogenous angiogenesis inhibition factors i.e. an
angiostatin–endostatin fusion cassette into mice bear-
ing a human xenografted glioblastoma tumor (Ohlfest
et al., 2005a) and metastasized colorectal carcinoma
tumors (Belur et al., 2011). In a suicide gene approach,
overexpressing HSV thymidine kinase type 1 (HSV-TK)
under the hTERT promoter yielded successful induction
of apoptosis and significant inhibition of tumor growth
(Song et al., 2009). Employing the SB system in T cell
adoptive immunotherapy has a great promise in treat-
ing hematological malignancies (Magnani et al., 2016).
In vivo, the delivery of the therapeutic gene is fre-
quently performed by hydrodynamic tail vein injections
of plasmids (Belur et al., 2003; Carlson et al., 2005;
Ohlfest et al., 2005b). By employing an adeno/SB hybrid
vector in a canine model, it was possible to demon-
strate that the technology was transferable from the
small to large animal (dog) model (Hausl et al., 2010).
Alternatively, the SB system is used to engineer cells ex
vivo that are administered/transplanted to the patient
to treat the disease. Remarkably, this approach has
already has been approved for a Phase 1, 2 clinical trials
to fight against cancer by using engineered T cells
(Deniger et al., 2016; Krishnamurthy et al., 2015;
Magnani et al., 2016; Singh et al., 2013; Singh et al.,
2015), and to treat age-related macular degeneration
(AMD, TargetAMD (http://www.targetamd.eu/)). In sum,
SB combines the integrating abilities of viral gene ther-
apy vectors needed for stable and long-lasting trans-
gene expression with the advantageous properties of
easy production, simpler handling and potentially safer
chromosomal integration profiles.
Sleeping beauty is a simple, unbiased and efficient
tool to gene function annotation
SB has also proved to be an invaluable tool in gene
annotation. By exploiting the local hopping feature of
the SB system, it was possible to decipher the genomic
neighborhood of a particular integration site by remobi-
lizing the transposons from individual chromosomes
(Keng et al., 2005; Kokubu et al., 2009). The greatest suc-
cess of SB has been in its use for phenotype-driven gen-
etics (Carlson et al., 2003; Elso et al., 2015; Horie et al.,
2003; Ivics & Izsvak, 2011; Izsvak et al., 2010; Moriarity &
Largaespada, 2011). Unlike a candidate-based strategy,
SB transposon-based gene trapping, enhancer trapping
and unbiased mutagenesis approach is suitable to iden-
tify genes with unexpected phenotypes (Balciunas et al.,
2004; Lu et al., 2007; Song & Cui, 2013).
Germline transgenesis
In the last two decades, the applicability of the SB sys-
tem as a transgenic agent has been systematically
tested in almost all of the existing animal model sys-
tems. SB was successfully used as a delivery vehicle for
germline transgenesis in a variety of vertebrate species
like in fish, including zebrafish (Danio rerio) (Balciunas
et al., 2004; Davidson et al., 2003), Nile tilapia
(Oreochromis niloticus) (He et al., 2013), medaka (Oryzias
latipes) (Grabher et al., 2003), in the amphibian Xenopus
laevis (Sinzelle et al., 2006), in rodents (Garcia Diaz et al.,
2016; Garrels et al., 2016c; Ivics et al., 2014c), rabbits
(Ivics et al., 2014b), swine (Garrels et al., 2011; Ivics et al.,
2014a) and cattle (Alessio et al., 2016; Garrels et al.,
2016b; Yum et al., 2016).
Pronuclear injection of the transposase in the form
of mRNA, the integration of the transgene flanked by
recognition sequences for the transposase is faster, and
can occur before the first cell division. This feature of
the SB system is highly beneficial in animals, possessing
a series of fast cell division that cannot be challenged
by using conventional non-viral or lentiviral vectors (e.g.
rabbits) (Ivics et al., 2014b; Katter et al., 2013). The SB
system has proven to be highly efficient to generate
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transgenic animals with a robust, whole-body transgene
expression, with no significant transgene silencing. This
feature also helps to establish tissue-specific transgenic
models (Katter et al., 2013). Combining SB transgenesis
with recombinase-mediated cassette exchange could
be employed to test multiple expression cassettes at a
single, well-characterized genomic locus (Garrels et al.,
2016a). Transgenic animals stably expressing specific
markers could be used to monitor dynamic processes
and establish various drug-testing schemes (Szebenyi
et al., 2015). Although transgenic techniques were trad-
itionally aimed at mice, the SB system could offer a feas-
ible solution to generate transgenic versions in a large
variety of animal models, and also in livestock (reviewed
in (Bosch et al., 2015)). Indeed, the employment of the
SB system could have a positive impact on livestock
production by facilitating an easy-to-use protocol to
generate transgenic farm animals (Hu et al., 2011).
Sleeping beauty for functional oncogenomics
Oncogenomic screens applying SB-mediated insertional
mutagenesis have been highly productive (Figure 9; for
review see (Mann et al., 2014; Moriarity et al., 2015;
Tschida et al., 2014)). For the oncogenic screens, the SB
system is modified to be a highly mutagenic agent. The
mutagenic SB transposons were designed to induce
either gain-of-function (GOF) or loss-of-function (LOF)
mutations when inserted in or near a gene based on its
genetic cargo. It is an effective method for candidate
gene discovery that can aid in distinguishing driver
from passenger mutations in cancer. This system has
been adapted for unbiased screens to identify drivers of
multiple cancer types. For example, these screens iden-
tified novel genes and pathways that were causative of
non-melanoma skin cancer (Quintana et al., 2013), colo-
rectal carcinoma (Starr et al., 2009; Starr et al., 2011),
non-viral hepato-cellular carcinoma (Keng et al., 2009),
leukemia and lymphoma (Collier et al., 2009), B-cell pre-
cursor acute lymphoblastic leukemia (BCP-ALL) (van der
Weyden et al., 2011), high grade astrocytoma (Bender
et al., 2010), Schwann cell sarcoma – in particular, malig-
nant peripheral nerve sheath tumor (Rahrmann et al.,
2013), hepatitis B virus-induced hepato-cellular carcin-
oma (Bard-Chapeau et al., 2014), histiocytic sarcoma
(Been et al., 2014), osteosarcoma (Moriarity et al., 2015),
prostate adenocarcinoma (Rahrmann et al., 2009) and
non-small cell lung carcinoma (Dorr et al., 2015).
Recently oncogenomic screens have also been adapted
for functional annotation of cancer genomes by ena-
bling insertional mutagenesis screens in
higher eukaryotes that are not amenable to germline
transgenesis, including humans (Chen et al., 2016;
Molyneux et al., 2014). These cancer screens apart from
revealing previously implicated genes have also led to
the discovery of several new potential drivers of cancers
thereby providing new targets for chemical and genetic
therapies.
Future directions
The future challenges of the SB-mediated therapeutic
approaches include a further improvement of safety
and efficacy. A tighter regulation of transposase expres-
sion would be necessary to guarantee the stability of
the transgene expression. Targeted gene insertion into
predetermined safe loci in the human genome is quite
ambitious, but might be feasible in the near future. The
efficacy of delivery is still a bottleneck problem of SB-
mediated applications. Coupling SB to cutting edge
non-viral delivery techniques should be further explored
(flow-through electroporation, nanotechnology, etc.).
Alternatively, coupling of SB for its safety features with
viral vectors for their efficient delivery could be an ideal
combination. The continuously accumulating know-
ledge on host–transposon interactions could further
fuel applications by lifting existing limitations.
In this revolutionary era, it became possible to genet-
ically engineer a number of organisms. The field of gen-
ome engineering is developing fast, and offers more
and more sophisticated tools to modify the genome.
Depending on the aim, the evaluation of pros and cons
of any particular engineering tool helps to identify the
most appropriate strategy. Importantly, the tools can be
combined with each other or with other recombination
systems. Remarkably, now it is possible to precisely edit
the genome (ZF-/TALEN-nucleases, CRISPR-Cas9 sys-
tem). For therapeutic applications, safety and feasibility
still remain the key issues. With respect to efficiency, a
targeted nuclease would be an ideal tool to knockout
or engineer a short specific DNA region. However, trans-
posons might be a better choice to deliver large cargos
in a variety of cell types. This is because in contrast to
targeted nuclease systems, transposons are not
dependent on the homology-dependent repair path-
ways of the host, whose efficiency represents a bottle-
neck of targeted genome-modifications in certain cell
types. Finally, while nuclease-coupled targeting systems
can precisely edit a desired genomic locus, they can
generate undesired double stand breaks in the genome
as off-target events. On the other hand, transposons do
not damage the genome with unwanted DSBs, but their
untargeted integration can be potentially mutagenic in
clinical applications. Targeting transposition to safe har-
bor genomic location could be feasible. For functional
genomic application (phenotypic screens), transposons
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Figure 9. Sleeping Beauty transposon-based functional oncogenomics. An overall scheme depicting key steps for employing the SB
system for oncogenomics. The conditional insertional mutagenesis begins with the generation of transgenic lineages of the chosen
model system, popularly referred to as the mutator (transposon) and jump-starter (transposase) lineages. The mutator lineage is
transgenic for a custom-engineered transposon (red double-headed arrow) that can be mobilized by the SB transposase (green pie).
The mutator transposon is designed so that by virtue, it can promote, alter or even terminate expression of endogenous reading
frames upon SB mediated insertion in either orientations eventually leading to gain and/or loss of functions. This entire scenario can
be rendered “conditional” by restricting the activity of SB to specific tissues or organs of choice by placing it under the command of
appropriate promoter. The double-transgenic animals are aged for development of relevant cancer phenotypes. The next step
involves the identification of the transposon integration sites that very likely resulted in the observed phenotypes. This primarily
involves extraction and digestion of the DNA from which these sites are recovered by LM-PCR, barcoded and sequenced by next gen-
eration sequencing. The recovered sites are mapped on the genome, and subjected to a statistical analysis to identify common inte-
gration sites (CISs) that were present in majority of the tumors. Shortlisted candidates are further validated by reverse genetic
approach as illustrated in the figure. Abbreviations: SA: splice acceptor; PA: poly-A tail; pro: promoter; SD: splice donor; GOF: gain of
function; LOF: loss of function; Chr: chromosome; LM-PCR: linker-mediated PCR; NGS: next generation sequencing; CIS: common inte-
gration sites. A color version of the figure is available online (see color version of this figure at www.informahealthcare.com/bmg).
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have the advantage of being unbiased with respect to
the sequences they mutagenize, whereas gene-editing
tools are biased by their very nature. It is likely, that
transposons will continue to uniquely contribute to the
genome-engineering toolbox for many years to come.
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